Although SARS-CoV-2 has gradually evolved into a seasonal respiratory ... To address the emerging H5N1 threat, the HKU and CVVT team used the influenza virus vector-based nasal spray vaccine platform ...

The study shows that the SARS-CoV-2 spike protein remains in the ... Other mRNA vaccines or vaccine types, such as vector- or ...

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant ... including SARS-CoV-2, norovirus ...

Researchers have pioneered an influenza virus vector-based nasal spray vaccine platform and developed a nasal spray H5N1 avian influenza vaccine, which has shown promise in animal models.

The viral vector derived from adenovirus, which infects cells readily but does not cause disease onset, serves as a carrier that delivers genetic materials that code for the SARS-CoV-2 spike ...

Our laboratory aims to understand the pathogenesis of SARS-CoV-2. One of our goals is to understand how environmental factors contribute to SARS-CoV-2 pathogenesis. We are currently funded through NIH ...

The SARS-CoV-2 pandemic crisis and COVID-19 disease ... they can readily develop immunity to the vaccine vector (Ad), which negates their utility for future vaccination. Non-human adenoviruses ...

Get Instant Summarized Text (Gist) A new method, Deep Novel Mutation Search (DNMS), uses AI to predict potential mutations in the SARS-CoV-2 spike protein. By employing a fine-tuned language model ...

SARS originated in Guangdong province , southern China and by the time it had been brought … Severe Acute Respiratory Syndrome (SARS) is a disease that first appeared in humans in November 2002.

Scientists have pioneered an influenza virus vector-based nasal spray vaccine platform and developed a nasal spray H5N1 avian influenza vaccine. During the early COVID-19 pandemic, this platform ...